Myzomib 2mg (Bortezomib)

Contact us for more information
Wishlist Compare

Myzomib 2mg (Bortezomib)

ManufacturerMYLAN PHARMACEUTICALS PVT LTDBrand nameMyzomibActive substanceBortezomibStrength2mgCategoryAnti CancerManufacturerMylan

Description  of  Myzomib 2mg (Bortezomib 2mg)

Bortezomib is a drug sold under the brand name of Myzomib 2mg (Bortezomib 2mg) which belongs to anti-neoplastic medicine, the main ingredient which is used as Bortezomib, which is available in the form of lyophilized powder Myzomib 2mg (Bortezomib 2mg) is a prime benign proteasome inhibitor; proteasome is a biological structure that clefts the proteins Pharmacological grouped as: anti-neoplastic agent or proteasome inhibitor The drug is an prescription drug given under the supervision of pharmacist

INDICATIONS of  Myzomib 2mg (Bortezomib 2mg)

Myzomib 2mg (Bortezomib 2mg) is majorly indicated for the treatment for patients suffering by following disease. Multiple myeloma Mantle cell lymphoma

MECHANISM OF ACTION  of  Myzomib 2mg (Bortezomib 2mg)

The drug Bortenat is a type of chymotrypsin like activity which is in form of unstable prohibitor of the 26S proteasome in human cells. The 26S proteasome is a group of protein that reduces the agglutinated proteins The various proteins are weakens by proteasome enzymes that make difficult to tumor cells persistence like cyclins, tumor suppressors, BCL-2 & cyclin dependent kinase inhibitors The functioning site of proteasome has Postglutamyl peptide hydrolysis activity Chymotrypsin like Trypsin like Prevention of these degenerations, sensitizes cells to apoptosis and cell arrest and leads to cell lysis

Absorption of  Myzomib 2mg (Bortezomib 2mg)

The Myzomib 2mg (Bortezomib 2mg) peak plasma level occurs as 509ng/ml

Distribution of  Myzomib 2mg (Bortezomib 2mg)

The Myzomib 2mg (Bortezomib 2mg) has nearly 83% of human plasma protein binding.

Metabolism of  Myzomib 2mg (Bortezomib 2mg)

Primarily metabolic pathway of Myzomib 2mg (Bortezomib 2mg) is occurs by deboronation to form 2-deboronated metabolites which are inactive as 26S proteasome inhibitors. In liver Myzomib 2mg (Bortezomib 2mg) is metabolized with the help of cytochrome P 450 enzymes 3A4, 2C19, & 1A2 by oxidation

Excretion of  Myzomib 2mg (Bortezomib 2mg)

The half life period of Myzomib 2mg (Bortezomib 2mg) occurs at 9 to 15 hours In single dose IV;


 SIDE EFFECTS  of  Myzomib 2mg (Bortezomib 2mg)

Most common side effects occurred after administration of Myzomib 2mg (Bortezomib 2mg) includes; Burning, crawling, itching, numbness, prickling ; Chest pain ; Black tarry stools; Bleeding gums ; Blood in urine ; Blurred vision ; Body aches, dizziness, faintness, nerve pain, painful urination, pale skin, runny nose, sore throat, stuffy nose, swollen glands, sunken eyes, ulcer, dry mouth, Cough producing mucus, ear congestion, loss of voice

Belching, bone pain, difficulty with moving & bowel movements, cold and shivering, loss of appetite, loss of taste, muscle cramps, muscle pain, stomach discomfort. Vomiting, loss of weight discomfort, increased sensitivity of pain & touch, irregular breathing, heart beats, swelling of peripheral organs, thickening of bronchial secretions


PRECAUTIONS  of  Myzomib 2mg (Bortezomib 2mg)

While taking Myzomib 2mg (Bortezomib 2mg) some adverse effects occurs care should be taken in the conditions like Cardiac toxicity Pulmonary toxicity like Acute Respiratory Distress Syndrome, pneumonitis, interstitial pneumonia, lung infiltration. Posterior reversible encephalopathy syndrome-stop the Myzomib 2mg (Bortezomib 2mg) therapy Myzomib 2mg (Bortezomib 2mg) leads to peripheral neuropathy like burning sensation, hyperesthesia, hypoesthesia, paresthesia, neuropathic pain Manage postural Hypotension by altering the antihypertensive agents, hydration, and administration of mineralocorticoids or sympathomimetics Gastrointestinal toxicity-fluid or electrolyte replacements have to take Thrombocytopenia and neutropenia Tumor lysis syndrome Hepatic toxicity Embryo fetal toxicity

DRUG INTERACTION of  Myzomib 2mg (Bortezomib 2mg)

Avoid interaction with st. Johns wort to decrease the exposure of Myzomib 2mg (Bortezomib 2mg) while concomitant with CYP3A4 inhibitors: there is a chance of getting Myzomib 2mg (Bortezomib 2mg) toxicity; so to reduce the dose of Myzomib 2mg (Bortezomib 2mg) Interaction with Strong CYP3A4 inducers: decrease the exposure of Myzomib 2mg (Bortezomib 2mg) while concomitant with melphalan-prednisone or dexamethasone alone No clinical effect on Myzomib 2mg (Bortezomib 2mg) exposure.

CONTRAINDICATION of  Myzomib 2mg (Bortezomib 2mg)

Myzomib 2mg (Bortezomib 2mg) is administer through IV bolus or subcutaneous; whereas intrathecal administration is contraindicated to the patients who are receiving Bortezomib Hypersensitivity reaction occurs in patients who are contraindicated to Myzomib 2mg (Bortezomib 2mg), boron, boric acid or glycine

PREGNANCY  & LACTATION  of Myzomib 2mg (Bortezomib 2mg)

Myzomib 2mg (Bortezomib 2mg) is not recommended in pregnancy condition. Myzomib 2mg (Bortezomib 2mg) causes fetal harm and leads to some adverse effect Breast feeding is not recommended

DOSAGE of  Myzomib 2mg (Bortezomib 2mg)

In adults:
Multiple myeloma:
Previously untreated multiple myeloma In the therapy: Bortenat dose 1.3mg/m2 should be given as 3 to 5 seconds via IV bolus or subcutaneous by interacting with tablet melphalan and prednisolone for nine 6 weeks treatment cycles Bortenat is taken for two times weekly, (day 1, 4, 8, 11, 22, 25, 29 and 32) for Cycles 1 over 4 Bortenat is taken once a week (day 1, 8, 22, and 29) for Cycles 5 over 9 Duration of Bortenat is 72 hours
In Relapse stage:
The usual dose of Bortenat is 1.3mg/m2 should be given via IV bolus or subcutaneous as two times for two weeks (day1, 4, 8, and 11) followed by a ten day rest course (day 12 through 21) Schedule of Treatment increased above 8 cycles may be taken once weekly for 4 weeks (day 1, 8, 15, and 22), followed by 13 day rest (day 23 over 35)
Important points:
Bortenat administrated alone or combination with dexamethasone therapy cycle require of Three week course
Mantle cell lymphoma:
The usual dose of Myzomib 2mg (Bortezomib 2mg)  for untreated mantle cell lymphoma is; Bortenat 1.3mg/m2 given as IV bolus given as two times weekly by concomitant with rituximab, cyclophospahmide, doxorubicin and tablet prednisolone for 2 weeks (day I, IV, VIII & XI) followed by rest period of 10 day (day II through 21). In Relapse stage: The regular dose of Bortenat is 1.3mg/m2 administered as IV bolus or subcutaneous 2 times for two weeks (day I, IV, VIII & XI) followed by 10 day rest period (day II through 21) The treatment followed for above 8 cycles may be taken for once weekly for 4 weeks (day 1, 8, 15 & 22), followed by rest of 13 day (days 23 through 35) Lyophilized powder form is Bortenat ; which is reconstituted by using 0.9% normal saline (NS) NaCl. Reconstituted the Myzomib 2mg (Bortezomib 2mg) in 2ml of 0.9% NS The route of administration is IV bolus Intrathecal not use for administration

STORAGE  of  Myzomib 2mg (Bortezomib 2mg)

Myzomib 2mg (Bortezomib 2mg) vial should be stored at 20℃ to 25℃ (68℉ to 77℉); excursion between 15℃ to 30℃ (59℉ to 86℉) Keep away from light and heat

MISSED DOSE of  Myzomib 2mg (Bortezomib 2mg)

If missed a dose the have it as soon possible or Missed dose should be swapped and continue the regular dosing schedule for avoiding adverse conditions. If missed dose occurs, it should not be resume and continue the next schedule.

Brand name:
Active substance:
Anti Cancer
1 Vial
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India